Price
Prices are end-of-day closes. This is a research view, the focus is on the fundamentals, quality and valuation below, not intraday price.
Smart Score
Below averageWe provide software and artificial intelligence (“AI”) designed to deliver a more accurate and clinically effective non-invasive solution for diagnosing and managing coronary artery disease (“CAD”), a leading cause of death worldwide. As of December 31, 2025, our Heartflow Platform has been used to assess CAD in more than 600,000 patients, including 219,000 in 2025 alone. We believe that we are the most widely adopted AI-powered test for CAD.
In the company’s own words · 10-K filed Mar 18, 2026 · SEC EDGAR
Business segments
Q3 2025 · $46.3MThe company’s own SEC segment disclosure.
- United States$42.9M93%
- United Kingdom$1.5M3%
- Japan$1.5M3%
- Rest Of Europe$349.0K1%
Heartflow, Inc. (HTFL) reported revenue of $64M in Q2 2026 (quarter ended Jun 30, 2026), up 48% from the same quarter a year earlier. That came with a gross margin of 83% and net loss of $16M. For the full year FY2025, revenue was $176M (+40% year on year) and net income −$117M. Its largest region in Q3 2025 (quarter ended Sep 30, 2025) was United States at $43M, 93% of the disclosed total, well ahead of United Kingdom at 3.3%.
Raw charts
9 series · TTMAs reported to the SEC, without any scoring.
Health Information Services
Ranks #8 of 13 by Smart Score